Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India

Table 1 Baseline characteristics of enrolled patients

Characteristics	Observations
Age (yr)
mean ± SD	56.24 ± 11.11
Age groups
≤ 35	16 (3.97)
36-50	97 (24.06)
51-65	207 (51.36)
66-80	75 (18.61)
Gender
Male	181 (44. 91)
Female	222 (55.09)
Type of cancer
Breast	101 (25.06)
Colon	63 (15.63)
Oral	43 (10.66)
Lung	29 (7.19)
Gall bladder	24 (5.95)
Epiglottis	13 (3.2)
Cervix	12 (2.97)
Rectum	12 (2.97)
Others1	106 (26.03)
Chemotherapy
Highly emetogenic	220 (54.6)
Moderately emetogenic	183 (45.4)
Chemotherapy cycles
1	75 (18.61)
2	89 (22.08)
3	30 (7.44)
4	90 (22.33)
5	52 (12.90)
> 5	67 (16.62)

Data presented as mean±standard deviation or frequency (%); Baseline demographic characteristics of patients enrolled in the study, distribution of there age (mean ± standard deviation), gender, type of cancer, type of chemotherapy and the chemotherapy cycle.

¹Others- Includes following cancers-Endometrial; Larynx, Stomach; B cell lymphoma; Ewing’s Sarcoma; Tonsil; Osteoblastoma; Mediastinal lymphadenopathy; Peri ampullary; Testis; Pyloric antrum; Pyriform fossa; Oropharynx; Ovary; Pancreas.

Table 2 Outcome assessments

Population	Number of participants	Acute phase, Number of participants (%)	Delayed phase, Number of participants (%)	Overall phase, Number of participants (%)
Overall	403	397 (98.01)	378 (93.79)	378 (93.79)
Highly emetogenic chemotherapy	220	214 (97.27)	206 (93.63)	206 (93.63)
Moderately emetogenic chemotherapy	183	181 (98.90)	172 (93.98)	172 (93.98)

Complete response rate in acute delayed and overall phase among patients on highly and moderately emetogenic chemotherapy regimen.

Table 3 Complete response rate among enroled patients

Chemothrapycycle	Number of participants	Acute phase-number of participants (%)	Delayed phase-number of participants (%)	Overall phase-number of participants (%)
1	75	73 (97.33)	68 (90.66)	68 (90.66)
2	89	88 (98.87)	86 (96.22)	86 (96.22)
3	30	28 (93.33)	27 (90.00)	27 (90.00)
4	90	80 (88.88)	75 (83.00)	75 (83.00)
5	52	52 (100.00)	51 (98.07)	51 (98.07)
> 5	67	65 (97.01)	63 (94.02)	63 (94.02)

Complete response rate in acute, delayed and overall phase among patients enrolled in various cycles of chemotherapy.